PIK3CA and nasopharyngeal carcinoma: This study is the first to provide evidence for the efficacy of the novel dual PI3K/mTOR inhibitor NVP-BEZ235 in preclinical models of NPC and it has a potential therapeutic value as treatment alone or in combination with CDDP targeting NPC.